RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai ChemPartner, a China CRO, extended its collaboration with Berkeley Lights Inc. of South San Francisco by installing BLI’s Beacon® Optofluidic platform to offer B Cell antibody discovery services to its clients. ChemPartner will combine BLI’s antibody discovery workflow for B cells with ChemPartner’s assays. The Beacon® platform can screen tens of thousands of plasma B cells or gene-edited cells automatically, speeding up a usually time-consuming process. The Beacon® platform enables plasma B cell characterization in less than a day.
Source: China Biotoday
